Jonathan Philip Britt

Every moment, a spotlight of attention roams our visual field to enhance detection of salient stimuli. While recent work suggests how the brain selects salient relevant stimuli (attentional focus), it is unknown if there are mechanisms that modulate attention to suit fluctuating target salience or internal needs (attentional strength). Here, using optical recordings and perturbations in mice performing a cued detection task, we report that rapid dynamics in both dorsal raphe (DR) activity and cortical serotonin (5HT) release selectively regulate attentional strength. In contrast to these rapid DR-5HT dynamics, we found previously reported reward-associated and slower dynamics were both unrelated to attention. Brief optogenetic DR-5HT suppression increased attentional strength and performance, whereas optogenetic excitation reduced attentional strength and performance. A computational model suggests DR-5HT’s inverse effects on attention arise from control of cortical suppression and divisive normalization. Collectively, our results demonstrate that the brain independently controls attentional strength and focus and defines rapid DR-5HT neuromodulation as a new regulator of attentional strength.

Summary: Dopamine regulates the frequency of motor actions, but it is unclear whether it similarly regulates the duration of discrete behaviors. Here, we show that dopamine signaling within the medial accumbens shell reinforces actions while simultaneously constraining their duration. When mice hold down a lever to continuously self-stimulate dopamine axons in the medial accumbens shell, hold-downs are rarely longer than 5 seconds, and higher stimulation frequencies elicit shorter, but more numerous, lever hold-downs. This disengaging property of medial accumbens shell dopamine also applies to consummatory behavior, as mice are quicker to both terminate and reinitiate bouts of licking paired with high frequency dopamine axon stimulation. Dopamine D1 receptors underpin this disengaging property of dopamine signaling, as we demonstrate a D1 agonist shortens both self-stimulation hold-downs and bouts of consummatory behavior. Altogether, we uncover an anatomically defined role of dopamine, which is to disengage its own reinforcing properties through D1 receptor signaling.

The Methyl-CpG-Binding Domain Protein family has been implicated in neurodevelopmental disorders. The Methyl-CpG-binding domain 2 (Mbd2) binds methylated DNA and was shown to play an important role in cancer and immunity. Some evidence linked this protein to neurodevelopment. However, its exact role in neurodevelopment and brain function is mostly unknown. Here we show that Mbd2-deficiency in mice (Mbd2−/−) results in deficits in cognitive, social and emotional functions. Mbd2 binds regulatory DNA regions of neuronal genes in the hippocampus and loss of Mbd2 alters the expression of hundreds of genes with a robust down-regulation of neuronal gene pathways. Further, a genome-wide DNA methylation analysis found an altered DNA methylation pattern in regulatory DNA regions of neuronal genes in Mbd2−/− mice. Differentially expressed genes significantly overlap with gene-expression changes observed in brains of Autism Spectrum Disorder (ASD) individuals. Notably, downregulated genes are significantly enriched for human ortholog ASD risk genes. Observed hippocampal morphological abnormalities were similar to those found in individuals with ASD and ASD rodent models. Hippocampal Mbd2 knockdown partially recapitulates the behavioral phenotypes observed in Mbd2−/− mice. These findings suggest that Mbd2 is a novel epigenetic regulator of genes that are associated with ASD in humans. Mbd2 loss causes behavioral alterations that resemble those found in ASD individuals.

Clinical studies have reported that the psychedelic lysergic acid diethylamide (LSD) enhances empathy and social behavior (SB) in humans, but its mechanism of action remains elusive. Using a multidisciplinary approach including in vivo electrophysiology, optogenetics, behavioral paradigms, and molecular biology, the effects of LSD on SB and glutamatergic neurotransmission in the medial prefrontal cortex (mPFC) were studied in male mice. Acute LSD (30 μg/kg) injection failed to increase SB. However, repeated LSD (30 μg/kg, once a day, for 7 days) administration promotes SB, without eliciting antidepressant/anxiolytic-like effects. Optogenetic inhibition of mPFC excitatory neurons dramatically inhibits social interaction and nullifies the prosocial effect of LSD. LSD potentiates the α-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) and 5-HT _2A , but not N -methyl-D-aspartate (NMDA) and 5-HT _1A , synaptic responses in the mPFC and increases the phosphorylation of the serine-threonine protein kinases Akt and mTOR. In conditional knockout mice lacking Raptor (one of the structural components of the mTORC1 complex) in excitatory glutamatergic neurons ( Raptor ^f/f :Camk2alpha-Cre ), the prosocial effects of LSD and the potentiation of 5-HT _2A /AMPA synaptic responses were nullified, demonstrating that LSD requires the integrity of mTORC1 in excitatory neurons to promote SB. Conversely, in knockout mice lacking Raptor in GABAergic neurons of the mPFC ( Raptor ^f/f :Gad2-Cre ), LSD promotes SB. These results indicate that LSD selectively enhances SB by potentiating mPFC excitatory transmission through 5-HT _2A /AMPA receptors and mTOR signaling. The activation of 5-HT _2A /AMPA/mTORC1 in the mPFC by psychedelic drugs should be explored for the treatment of mental diseases with SB impairments such as autism spectrum disorder and social anxiety disorder.